A study found that patients with ankylosing spondylitis who had an inadequate response to secukinumab at 16 weeks did not see any additional benefit at 52 weeks from an escalated dose. No new safety signals were observed during the study. The study followed up on a previous phase 4 trial, ASLeap, where patients with AS demonstrated inadequate response after 16 weeks of secukinumab. Results showed that both the standard dose and escalated dose group had similar rates of inactive disease and treatment-emergent adverse events at week 52, suggesting that dose escalation may not be beneficial for all patients with an inadequate response.
Source link
Higher secukinumab dose yields no clinical difference after inadequate response in AS
